COMMUNIQUÉS West-GlobeNewswire

Kura Oncology to Participate in Three Investor Conferences in September
01/09/2026
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at [...]
Arletta Pharma Solutions Appoints Jeannette Jager-van Dijk as Chief Executive Officer
01/09/2026
www.arlettapharmasolutions.com Global women’s health executive to lead Arletta in its development strategy focused on advancing Lybrido™’s (sildenafil/testosterone) Phase 2 MONARCH study following positive FDA [...]
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
01/09/2026
–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen– – Improvements in cognition and behavior sustained through 4 years, in addition to [...]
Pyxis Oncology to Participate in Upcoming Investor Conferences
01/09/2026
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Interim [...]
FocalTherics™ to Present at the H.C. Wainwright 28th Annual Global Investment Conference
01/09/2026
Company to Present and Host 1x1 Investor Meetings on Tuesday and Wednesday, September 15th-16th, 2026 FocalTherics ™ to Present at the H.C. Wain w right 28 th Annual Global Investment Conference Company to Present and [...]
F2G Announces Posters Accepted for Presentation at Upcoming Medical Meetings
01/09/2026
MANCHESTER, United Kingdom, Sept. 01, 2026 (GLOBE NEWSWIRE) -- F2G Ltd., today announced abstracts accepted for presentation at the MSGERC 2026 Biennial Meeting in September and ISPOR Europe 2026 in November. Details of [...]
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/09/2026
CLEVELAND, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved [...]
Ardelyx to Participate in Upcoming Investor Conferences
01/09/2026
WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative [...]
BridgeBio to Participate in September Investor Conferences
01/09/2026
PALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for [...]
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
01/09/2026
– LUMUS trial did not meet its primary and secondary endpoints in the overall trial population – – Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-high) support [...]
Vera Therapeutics to Participate at Upcoming Investor Conferences
01/09/2026
BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company’s management team will present and participate in [...]
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
01/09/2026
Vancouver, Canada, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen [...]
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
01/09/2026
ARLINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek"), a CLIA-registered precision health and clinical genomics company, today announced that they have [...]
Applied Biologics Activates First Clinical Site in Phase 3 BIOxHEAL™ Trial
01/09/2026
Milestone marks transition to active site-level execution with patient screening and enrollment expected to begin shortly SCOTTSDALE, Ariz., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical [...]
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
01/09/2026
GAITHERSBURG, Md., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and [...]
CytomX Therapeutics to Present at Upcoming September Investor Conferences
01/09/2026
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will [...]
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
01/09/2026
EMERYVILLE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative [...]
Resolution Therapeutics partners with the Blood Centers of America, Inc. to support broad patient access to its experimental Regenerative Macrophage Therapy in the U.S.
01/09/2026
Partnership will support Resolution’s pivotal clinical program in 2027, as well as future commercial preparedness for RTX001, its lead asset in patients with end-stage liver disease (ESLD) Primary goal is to ensure [...]
ENA Respiratory Awarded Biointelect Venturer Funding to Support New Study in Asthma Patients of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
01/09/2026
MELBOURNE, Australia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing host defence enhancers for the prevention of complications associated with respiratory viral [...]

Pages